Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 24, 2013Experimental and Therapeutic MedicineOpen Access

Postconditioning with rosuvastatin reduces myocardial ischemia-reperfusion injury by inhibiting high mobility group box 1 protein expression

View Full Paper
Ask AI
Bookmark
Share

Key result

Rosuvastatin postconditioning significantly decreased myocardial infarct size compared to ischemia-reperfusion alone (28.9±3.7% vs. 52.8±4.4%, P<0.05) in a rat model.

Why the study?

Does postconditioning with rosuvastatin reduce myocardial ischemia-reperfusion injury in rats?

Population

Anesthetized male rats subjected to myocardial ischemia for 30 min

Design

Preclinical

Follow-up

4 hours of reperfusion

Authors

XDXianjin DuXHXiaorong HuJWJie Wei

Discussion

Loading...

Member takes

Overview

Rosuvastatin postconditioning may protect against experimental ischemia-reperfusion injury; leaves open translation to clinical cardioprotection.

Structured PICO

Does postconditioning with rosuvastatin reduce myocardial ischemia-reperfusion injury in rats?

P
Population
40 male Sprague-Dawley rats subjected to a 30-minute left anterior descending coronary artery occlusion followed by 4 hours of reperfusion.
I
Intervention
Rosuvastatin 10 mg/kg i.v. administered once 5 min prior to reperfusion
O
Outcome
Myocardial ischemia-reperfusion injury assessed by infarct size, lactate dehydrogenase (LDH), creatine kinase (CK), superoxide dismutase (SOD) activities, malondialdehyde (MDA) levels, and HMGB1 expressionsurrogate

Main Result

Absolute Event Rate: 28.9% vs 52.8%

p-value: p=<0.05

Rosuvastatin postconditioning reduces myocardial ischemia-reperfusion injury in a rat model, potentially through the inhibition of HMGB1 expression.

Limitations

  • Only the effect of rosuvastatin postconditioning on myocardial I/R injury and HMGB1 expression was investigated.
  • The precise mechanisms underlying the observations require future investigation.

Cite This Study

Du et al. (2013) studied Myocardial ischemia-reperfusion injury (n=40). Rosuvastatin vs. Ischemia and reperfusion (I/R) without rosuvastatin was evaluated on Infarct size (percentage of risk area volume) (p=<0.05). Rosuvastatin postconditioning significantly decreased myocardial infarct size compared to ischemia-reperfusion alone (28.9±3.7% vs. 52.8±4.4%, P<0.05) in a rat model.

synapsesocial.com/papers/6aa4b49e5b13064ba7dc3d56https://doi.org/10.3892/etm.2013.1362
View Full Paper
Ask AI
Bookmark
Share